Core Insights - The revised wholesale acquisition cost (WAC) for Ionis Pharmaceuticals' drug Tryngolza will take effect on April 1, with a new annual price set at $40,000, higher than the previously guided range of $10,000 to $20,000 [3][4] - The pricing adjustment is strategically timed to align with payer contracting cycles, indicating Ionis is positioning for formulary inclusion ahead of a broader market launch [3] - Analysts are optimistic about the potential for regulatory approval by the June 30 PDUFA date, which could significantly expand the market opportunity for Tryngolza [7] Pricing Strategy - The new pricing aligns more closely with expectations based on clinical outcomes, particularly the drug's impact on pancreatitis risk demonstrated in CORE studies [4] - The pricing shift has led analysts to revisit their financial models, with previous assumptions based on a net annual price of approximately $20,400 [5] - The revised pricing could enhance peak sales estimates, with previous projections exceeding $2 billion in sHTG, potentially reaching $2.6 billion with a 20% U.S. market penetration [6] Market Outlook - The combination of competitive pricing, strong clinical data, and broader indication potential positions Tryngolza as a key growth driver for Ionis [7] - Ionis Pharmaceuticals shares experienced a 3.74% increase, reaching $75.42 at the time of publication [8]